Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC210 in Post-Traumatic Stress Disorder
NCT04951076Phase 2Completed
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing BNC210 with Placebo (2 arms). Primary endpoint: Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder Scale for DSM-5 Total Symptom Severity Scores at 12 weeks. Started Jul 2021; status: completed.
02
Drugs
soclenicant
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04951076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951076.